PL4062916T3 - Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje - Google Patents

Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje

Info

Publication number
PL4062916T3
PL4062916T3 PL22165669.7T PL22165669T PL4062916T3 PL 4062916 T3 PL4062916 T3 PL 4062916T3 PL 22165669 T PL22165669 T PL 22165669T PL 4062916 T3 PL4062916 T3 PL 4062916T3
Authority
PL
Poland
Prior art keywords
certain mutations
fabry patients
treating fabry
treating
patients
Prior art date
Application number
PL22165669.7T
Other languages
English (en)
Inventor
Jeff Castelli
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4062916(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of PL4062916T3 publication Critical patent/PL4062916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL22165669.7T 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje PL4062916T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762512458P 2017-05-30 2017-05-30
US201862626953P 2018-02-06 2018-02-06

Publications (1)

Publication Number Publication Date
PL4062916T3 true PL4062916T3 (pl) 2025-03-17

Family

ID=65803261

Family Applications (4)

Application Number Title Priority Date Filing Date
PL22165669.7T PL4062916T3 (pl) 2017-05-30 2018-05-30 Leczenie pacjentów z chorobą Fabry’ego mających pewne mutacje
PL23219933.1T PL4327869T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL23219949.7T PL4324522T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL18733415.6T PL3630114T3 (pl) 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL23219933.1T PL4327869T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL23219949.7T PL4324522T3 (pl) 2017-05-30 2018-05-30 Sposoby leczenia pacjentów z chorobą Fabry’ego mających zaburzenie czynności nerek
PL18733415.6T PL3630114T3 (pl) 2017-05-30 2018-05-30 Migalastat do leczenia pacjentów z chorobą Fabry'ego z zaburzeniem czynności nerek

Country Status (14)

Country Link
EP (9) EP3630114B9 (pl)
CN (4) CN111278438A (pl)
DK (4) DK4324522T3 (pl)
ES (5) ES3002433T3 (pl)
FI (4) FI4062916T3 (pl)
HR (4) HRP20260346T1 (pl)
HU (2) HUE069837T2 (pl)
LT (4) LT4324522T (pl)
PL (4) PL4062916T3 (pl)
PT (4) PT4062916T (pl)
RS (4) RS67861B1 (pl)
SI (4) SI4327869T1 (pl)
SM (4) SMT202600114T1 (pl)
TW (4) TWI894750B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220313670A1 (en) * 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) * 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2012125402A2 (en) * 2011-03-11 2012-09-20 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
WO2018017721A1 (en) 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
TWI775453B (zh) 2022-08-21
DK3630114T3 (da) 2024-01-29
RS67849B1 (sr) 2026-03-31
SI4062916T1 (sl) 2025-04-30
EP4327869A3 (en) 2024-05-22
TW201900165A (zh) 2019-01-01
HRP20240061T1 (hr) 2024-03-29
EP4324522A2 (en) 2024-02-21
CN119587544A (zh) 2025-03-11
EP4635496A1 (en) 2025-10-22
ES2970419T3 (es) 2024-05-28
EP4062915A1 (en) 2022-09-28
HUE069837T2 (hu) 2025-04-28
CN117357524A (zh) 2024-01-09
FI4324522T3 (fi) 2026-03-09
DK4324522T3 (da) 2026-03-16
SI3630114T1 (sl) 2024-03-29
LT4327869T (lt) 2026-03-25
PT4327869T (pt) 2026-03-12
SMT202400037T1 (it) 2024-03-13
EP4245366A9 (en) 2023-12-06
FI3630114T3 (fi) 2024-01-30
DK4062916T3 (da) 2025-01-13
FI4062916T3 (fi) 2025-01-10
EP4245366A2 (en) 2023-09-20
RS66376B1 (sr) 2025-02-28
EP4327869B1 (en) 2025-12-10
SMT202500016T1 (it) 2025-03-12
ES3052647T3 (en) 2026-01-12
EP4374918B1 (en) 2025-07-16
HUE065615T2 (hu) 2024-06-28
EP4245366A3 (en) 2023-11-29
EP4062916A1 (en) 2022-09-28
FI4327869T3 (fi) 2026-03-09
TWI795408B (zh) 2023-03-11
TWI894750B (zh) 2025-08-21
SMT202600114T1 (it) 2026-05-12
SMT202600113T1 (it) 2026-05-12
PT4324522T (pt) 2026-03-13
EP3630114B9 (en) 2026-05-20
HRP20260335T1 (hr) 2026-04-10
HRP20241738T1 (hr) 2025-02-28
EP4324522A3 (en) 2024-05-22
LT4324522T (lt) 2026-03-25
PT3630114T (pt) 2024-02-01
RS65230B1 (sr) 2024-03-29
LT3630114T (lt) 2024-02-12
EP4327869A2 (en) 2024-02-28
EP4374918A3 (en) 2024-08-14
EP4062916B1 (en) 2024-10-09
PL4327869T3 (pl) 2026-04-27
ES3002433T3 (en) 2025-03-06
PT4062916T (pt) 2025-01-13
ES3065434T3 (en) 2026-05-06
TW202440104A (zh) 2024-10-16
EP4374918A2 (en) 2024-05-29
SI4327869T1 (sl) 2026-05-29
EP3630114B1 (en) 2023-11-01
LT4062916T (lt) 2025-01-10
TW202322814A (zh) 2023-06-16
EP3630114A1 (en) 2020-04-08
CN111278438A (zh) 2020-06-12
SI4324522T1 (sl) 2026-05-29
PL4324522T3 (pl) 2026-04-27
CN120732857A (zh) 2025-10-03
EP4324522B1 (en) 2025-12-10
EP4327868A2 (en) 2024-02-28
PL3630114T3 (pl) 2024-03-25
DK4327869T3 (da) 2026-03-16
HRP20260346T1 (hr) 2026-04-24
TW202140000A (zh) 2021-11-01
RS67861B1 (sr) 2026-04-30
ES3065413T3 (en) 2026-05-06

Similar Documents

Publication Publication Date Title
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
GB201608885D0 (en) Treatment
LT3452475T (lt) Tetrahidropirimidodiazepino ir tetrahidropiridodiazepino junginiai, skirti skausmo ir su skausmu susijusių būsenū gydymui
GB201800546D0 (en) Treatment
ZA201705847B (en) Treatment of pain
GB201604658D0 (en) Treatment for pain
SMT202500016T1 (it) Trattamento di pazienti affetti da malattia di fabry aventi determinate mutazioni
EP3277726A4 (en) Pain treatment
GB201718985D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201713650D0 (en) Treatment
GB201704949D0 (en) Combination treatment
GB201706955D0 (en) Treatment
GB201507717D0 (en) Treatment couch
GB201505205D0 (en) Treatment for pain
GB201504688D0 (en) Treatment for pain
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
AU2015901215A0 (en) Pain treatment
AU2015901216A0 (en) Pain treatment
GB201506944D0 (en) Therapeutic treatment
GB201609683D0 (en) Treatment